NASDAQ:SYNH - Syneos Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$54.74 +0.86 (+1.60 %)
(As of 02/18/2019 02:57 AM ET)
Previous Close$54.74
Today's Range$52.3157 - $54.77
52-Week Range$31.10 - $54.77
Volume801,469 shs
Average Volume586,637 shs
Market Capitalization$5.65 billion
P/E Ratio28.22
Dividend YieldN/A
Beta1.51
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic collaboration with Elligo Health Research. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.67 billion
Cash Flow$3.9128 per share
Book Value$28.97 per share

Profitability

Net Income$-138,460,000.00

Miscellaneous

Employees21,000
Market Cap$5.65 billion
OptionableOptionable

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) released its earnings results on Thursday, August, 2nd. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.01. The firm earned $1.07 billion during the quarter, compared to analysts' expectations of $1.09 billion. Syneos Health had a positive return on equity of 8.67% and a negative net margin of 0.84%. Syneos Health's revenue was up 315.5% compared to the same quarter last year. View Syneos Health's Earnings History.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Syneos Health.

What price target have analysts set for SYNH?

10 brokerages have issued 12 month price targets for Syneos Health's stock. Their forecasts range from $45.00 to $60.00. On average, they anticipate Syneos Health's share price to reach $54.75 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View Analyst Price Targets for Syneos Health.

What is the consensus analysts' recommendation for Syneos Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

Has Syneos Health been receiving favorable news coverage?

News stories about SYNH stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneos Health earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.

Who are some of Syneos Health's key competitors?

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair MacDonald, CEO & Director (Age 49)
  • Dr. Michael Gibertini, Pres of Clinical Devel. for Therapeutic Bus. Units (Age 61)
  • Mr. Michael Adam Bell, Consultant (Age 63)
  • Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
  • Dr. Judith Ng-Cashin, Chief Scientific Officer

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Thomas H Lee Partners LP (18.61%), BlackRock Inc. (8.20%), Mackenzie Financial Corp (3.10%), Dimensional Fund Advisors LP (1.49%), Principal Financial Group Inc. (1.29%) and Northern Trust Corp (1.11%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.

Which institutional investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Monarch Partners Asset Management LLC, Dimensional Fund Advisors LP, Mesirow Financial Investment Management Equity Management, Bank of America Corp DE, Barclays PLC, GW&K Investment Management LLC and Mackay Shields LLC. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health.

Which institutional investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Mackenzie Financial Corp, Principal Financial Group Inc., Thrivent Financial for Lutherans, Amundi Pioneer Asset Management Inc., D. E. Shaw & Co. Inc., Phocas Financial Corp. and Rhumbline Advisers. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $54.74.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $5.65 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.

What is Syneos Health's official website?

The official website for Syneos Health is http://www.incresearch.com.

How can I contact Syneos Health?

Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  748
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel